SUDA Pharmaceuticals Ltd's (ASX:SUD) (FRA:E4N) Michael Baker introduces Anastsios Karadimitris after signing an exclusive licence agreement with Imperial College London for a novel invariant Natural Killer T (iNKT) cell therapy platform. As a blood cancer specialist, Karadimitris how the iNKT cell therapy platform works and can be used in conjunction with chimeric antigen receptors (CARs). The CAR-iNKT cells are expected to be suitable for off-the-shelf dosing - as one healthy donor can supply cells to treat many patients. Baker explains how the proceeds of the recent heavily oversubscribed placement that raised $3.65 million is going to be invested.
Suda Pharmaceuticals' introduce novel iNKT cell therapy platform from Imperial College London
